Kleo Pharmaceuticals is a company focused on developing immunotherapy compounds that enhance the body's immune system to target cancer cells. Their compounds are non-immunogenic, highly stable, and lower in molecular weight, making them faster and less costly to design and produce. Founded by Dr. David Spiegel and Roy Prieb, the company is based on intellectual property from the Spiegel Lab at Yale University. Kleo Pharmaceuticals was acquired by Biohaven Pharmaceutical in January 2021. They are developing two types of small molecules, Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs), which have the potential to treat cancer, infectious diseases, and other indications. Kleo Pharmaceuticals' technology represents a breakthrough in safer, more efficacious, and convenient treatment options.